Conclusion
Infliximab is a proven powerful agent that is an asset to psoriasis patients as a monotherapy. It has the highest efficacy after 12 weeks of therapy. Infliximab provide significant QoL improvement, like any medication. However, there is a risk of rare severe adverse events. 12 Infliximab requires intravenous infusion approximately every 8 weeks and patients enjoy the freedom from therapy.
Once again, it should be restated that Psoriasis is typically a chronic disease and there is a need for safe long-term therapies.
